THE FDA MAY NOT REGULATE TOBACCO PRODUCTS AS DRUGS OR AS MEDICAL DEVICES

Authors
Citation
Ra. Merrill, THE FDA MAY NOT REGULATE TOBACCO PRODUCTS AS DRUGS OR AS MEDICAL DEVICES, Duke law journal, 47(6), 1998, pp. 1071-1094
Citations number
18
Categorie Soggetti
Law
Journal title
ISSN journal
00127086
Volume
47
Issue
6
Year of publication
1998
Pages
1071 - 1094
Database
ISI
SICI code
0012-7086(1998)47:6<1071:TFMNRT>2.0.ZU;2-1
Abstract
Professor Richard Merrill contends that the Federal Food, Drug, and Co smetic Act does not grant the FDA regulatory authority over cigarettes and smokeless tobacco products. the fact that Congress did not expres sly deny the FDA regulatory authority over tobacco cannot, Professor M errill argues, be used to infer such authority. This inference is part icularly inappropriate in the case of tobacco regulation, he maintains , because there is compelling evidence that Congress had no intention of delegating this authority to the FDA. He is unpersuaded that presid ential approval legally sanctions the FDA's claim of authority by gran ting it a superficial political legitimacy. Finally, he reminds us of the FDA's own repeated denials of jurisdiction over tobacco products, and he recalls the numerous times that Congress passed legislation dir ected at tobacco without granting the FDA any role in its regulation. Professor Merrill's Essay, like the other pieces in this volume, was w ritten after the United States District Court for the Middle District of North Carolina decided Coyne Beahm v. FDA,(1) but before a three ju dge panel of the United States Court of Appeals for the Fourth Circuit reversed that decision in Brown & Williamson Tobacco Corp. v. FDA.(2) In Coyne Beahm, the District Court held that the Federal Food, Drug, and Cosmetic Act authorized the FDA to regulate tobacco products, but not tobacco advertising. The Fourth Circuit rejected the District Cour t's jurisdictional ruling and invalidated the FDA's regulations in the ir entirety. The Clinton Administration has since requested an en banc rehearing before the Fourth Circuit.(3).